Liu Jun - Fundamental research - Excellence in Research
Chongqing Medical University - China
NOTABLE PUBLICATION
🎓 EDUCATION BACKGROUND
Liu Jun received a bachelor's degree from Southwest Medical University in 2016 and later earned a master's degree from Chongqing Medical University in 2024. Specializing in integrated Chinese and Western medicine, Liu Jun is an attending doctor in Internal Medicine, with a particular focus on the prevention and treatment of chronic kidney disease. His academic journey has provided a strong foundation in both traditional Chinese medicine and modern medical practices, allowing him to approach complex health issues with a holistic perspective.
đź©ş RESEARCH INTERESTS
Liu Jun’s research is centered on the integration of Chinese and Western medicine for the prevention and treatment of chronic kidney disease (CKD). His work explores the therapeutic potential of combining traditional herbal remedies, such as Astragaloside IV, with modern medical techniques. By focusing on the synergistic effects of these two medical traditions, he aims to develop more effective treatments for CKD, particularly in the context of complex conditions like diabetic kidney disease (DKD).
🔬 KEY STUDY ON ASTRAGALOSIDE IV
Liu Jun has conducted groundbreaking research on Astragaloside IV (AS-IV), a bioactive compound from the Astragalus membranaceus root, used in Chinese medicine to treat CKD. His study revealed that AS-IV plays a significant role in the treatment of diabetic kidney disease by mitigating oxidative stress, ferroptosis, and mitochondrial dysfunction in renal tubular epithelial cells. This research provides new insights into the renoprotective mechanisms of AS-IV and highlights its potential for clinical application in DKD management.
🧬 RESEARCH METHODS AND FINDINGS
In his study, Liu Jun employed advanced research techniques, including network pharmacology, proteomics, molecular docking, and molecular dynamics simulation, to uncover the molecular mechanisms by which AS-IV exerts its protective effects. His findings demonstrated that AS-IV enhances renal function, reduces oxidative stress, and prevents mitochondrial damage in DKD models. The study also identified key proteins—HMOX1, FTH1, and TFR1—that interact with AS-IV, further supporting its role in combating mitochondrial dysfunction and ferroptosis in DKD.
đź“š PUBLICATIONS
Liu Jun has published four SCI papers, each contributing to the understanding of integrated Chinese and Western medicine in the treatment of chronic kidney disease. His work on AS-IV and its effects on DKD has been particularly impactful, offering new avenues for the development of renoprotective therapies. His publications reflect a commitment to advancing the field of nephrology through innovative research that bridges traditional and modern medical practices.
🏅 CONTRIBUTIONS TO INTEGRATED MEDICINE
Through his research, Liu Jun is making significant contributions to the field of integrated Chinese and Western medicine. His work not only advances the scientific understanding of traditional herbal compounds like AS-IV but also paves the way for their integration into modern medical treatments. His research has the potential to improve patient outcomes by providing more comprehensive and effective therapies for chronic kidney disease, particularly in the context of diabetes.
🌟 PROFESSIONAL GOALS
Looking ahead, Liu Jun aims to continue his research in integrated medicine, focusing on the development of new strategies for the treatment of chronic kidney disease. His goal is to further explore the potential of traditional Chinese medicine in combination with Western medical approaches, ultimately contributing to the creation of more holistic and effective treatment options for patients with complex medical conditions like DKD.
NOTABLE PUBLICATION
A New Strategy for Astragaloside IV in the Treatment of Diabetic Kidney Disease: Analyzing the Regulation of Ferroptosis and Mitochondrial Function of Renal Tubular Epithelial Cells
Authors: Liu, J., Yang, K., Zhou, L., Zhang, Y., Cao, W.
Year: 2024
Journal: International Immunopharmacology
Proteomic and Lipidomic Analysis of the Mechanism Underlying Astragaloside IV in Mitigating Ferroptosis Through Hypoxia-Inducible Factor 1α/Heme Oxygenase 1 Pathway in Renal Tubular Epithelial Cells in Diabetic Kidney Disease
Authors: Liu, J., Ren, J., Zhou, L., Cao, W., Zhang, Y.
Year: 2024
Journal: Journal of Ethnopharmacology
Integration of Network Pharmacology and Serum Medicinal Chemistry to Investigate the Pharmacological Mechanisms of QiZhuYangGan Decoction in the Treatment of Hepatic Fibrosis
Authors: Deng, J.-W., Yuan, S., Shi, L.-P., Yang, Q., Cao, W.-F.
Year: 2024
Journal: Journal of Ethnopharmacology